G56W1 in Women With Postmenopausal Osteoporosis

Postmenopausal Osteoporosis Clinical Trial

Official title:

Two-dose, Positive Drug Control, Multicentre, Randomized, Double-blind Study of Recombinant Human Parathyroid Hormone for Injection(rhPTH)(1-34) Once a Week to Treat Postmenopausal Osteoporosis Women for the Evaluation the Pharmacokinetics and Safety and to Explore Therapeutic Effects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03720886
• Other study ID #: G56W1A201
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 1, 2018
• Est. completion date: August 31, 2020

Study information

• Verified date: October 2018
• Source: Shenzhen Salubris Pharmaceuticals Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The anticipated time on study treatment is 24 weeks, and the target sample size is 148 individuals.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 148
• Est. completion date: August 31, 2020
• Est. primary completion date: May 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female, capable of self - motivation , 45 years old = age = 75 years old.

• Natural menopause for 3 years or more; or surgical menopause for 3 years or more (surgery needs to be performed after 40 years old), for women with surgical menopause, estradiol(E2)< 25 pg/ml and follicle stimulating hormone(FSH) > 40mIU/ml should be met.

• Weight = 40kg , 18 = body mass index(BMI)= 30 .

• Meets one of the following diagnostic criteria for osteoporosis, and = 3 vertebral bodies of L1-4 can be measured by bone mineral density using the DXA method.

1. Brittle fracture of the hip or vertebral body, and the bone density measurement T- score< -1.0.

2. The T- score of the central axis bone mineral density or the 1/3 bone density of the distal radius of the tibia was =-2.5 measured by DXA .

3. Bone density measurements were consistent with low bone mass ( -2.5 < T- value < -1.0 ) and combined with proximal humerus, pelvic or forearm distal brittle fractures.

• to participate in the trial and sign the informed consent form.

Exclusion Criteria:

• to have diseases affecting calcium or bone metabolism that are not effectively controlled, such as primary hyperparathyroidism or hyperthyroidism, Paget's bone disease, hypercalcemia, hypocalcemia, active urolithiasis.

• Secondary osteoporosis, such as osteomalacia, rheumatoid arthritis, gout, multiple myeloma, etc.

• Severe lumbar anatomical abnormalities which affecting DXA bone mineral density measurement, such as severe scoliosis.

• Patients who have been treated for anti-osteoporosis before random enrollment:

1. Patients who received parathyroid hormone(PTH) therapy before random enrollment (including clinical trials of similar products).

2. Patients who received bisphosphonate injection within 1 year prior to random enrollment or received bisphosphonate oral administration within 3 months for > 2 weeks prior to enrollment.

3. Systemic treatment of androgen, estrogen, and selective estrogen receptor modulator(SERM) preparations within 3 months > 2 weeks prior to random enrollment.

4. Three months before randomized to receive of heparin, warfarin, anticonvulsants (except benzodiazepines), digoxin accumulated for> 2 weeks.

5. In the 3 months prior to random enrollment , received calcitonin, vitamin K preparation, active vitamin D3 preparation, oral or intravenous glucocorticoid treatment for > 4 weeks.

• Suffering from severe kidney disease, uncontrolled high blood pressure ( =150/100 mmHg ), symptomatic ischemic heart disease, cerebral infarction or obliterative atherosclerosis, malignancy, and other serious underlying diseases.

• Laboratory tests indicates abnormal, including any of the following indicators abnormalities (according to the normal range of each center, after consideration of the investigator with clinical considerations, such as caused by operational procedures, etc., after discussion with the sponsor, may allow retesting once) .

1. Alkaline phosphatase(ALP)>1.5 times the upper limit of normal.

2. Aspartate transaminase(AST) or alanine aminotransferase(ALT) or total bilirubin(TBIL) > 2.0 times the upper limit of normal.

3. Glycated hemoglobin(HbA1c )= 7.0% .

4. White blood cell(WBC)< 3.5×10^9 /L , Hb<100g/L or Plt<90×10^9 /L.

5. Thyroid-stimulating hormone(TSH)<0.01 mIU/L (mU/L) or TSH>10 mIU/L (mU/L) .

6. Parathyroid hormone(PTH)>1.5 times the upper limit of normal.

7. Serum creatinine(SCr)>1.2 times the upper limit of normal.

8. Serum total calcium(SCa)> normal upper limit.

• Subjects who had significant clinical significance including HIV , hepatitis B, hepatitis C, and syphilis ( hepatitis B virus carriers can be enrolled ) .

• Heavy Smoking (average of more than 10 / day) and / or alcohol addicted (converted to pure alcohol 30 ml / day or more) .

• Recent drug abuse or drug dependence evidence.

• Those who are allergic to test drugs / control drugs or biological products.

• Included in other interventional clinical trials within 3 months of the study.

• Been undergone radiation therapy for bones.

• Mental illness or any cause of cognitive impairment.

• Patients who were considered unsuitable for the study based on risk benefits by investigators.

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Postmenopausal
• Postmenopausal Osteoporosis

Intervention

Biological:
• rhPTH(1-34) 28.2µg
Administered by subcutaneous injection
• rhPTH(1-34) 56.5µg
Administered by subcutaneous injection
• teriparatide acetate(Teribone™)
Administered by subcutaneous injection

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing
China	The West China Second UniversityHospital of Sichuan University	Chengdu	Sichuan
China	West China Hospital,Sichuan University	Chengdu	Sichuan
China	Nanjing Drum Tower Hospital	Nanjing	Jiangsu
China	Zhongda Hospital, Southeast University	Nanjing	Jiangsu
China	Huadong Hospital Affiliated to Fudan University	Shanghai	Shanghai
China	Shanghai Sixth People's Hospital	Shanghai	Shanghai
China	Tianjin Hospital	Tianjin	Tianjin
China	Chongqing Three Gorges Central Hospital	Wanzhou	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage change in bone density of the lumbar spine ( L1-4 ) from baseline to 24 weeks after treatment	bone mineral density(BMD) measured by dual energy x-ray absorptiometry (DXA)	Baseline,week 24
Secondary	Evaluate the rate of change of Procollagen I N-terminal peptide(PINP),Serum cross-linked C-terminal telopeptide of type I collagen(s-CTX) ,Bone alkaline phosphatase(BALP) , and blood calcium from baseline	Central lab will be used	Baseline,week 24
Secondary	The percentage change of total hip bone density from baseline to 24 weeks after G56W1 treatment	BMD measured by DXA	Baseline,week 24
Secondary	Maximum plasma concentration (Cmax)	serum parathyroid hormone(PTH) will be tested for all pharmacokinetics parameters	Baseline,week 1,week 4,week 12,week 24
Secondary	Area under the plasma concentration versus time curve (AUC)	serum PTH will be tested for all pharmacokinetics parameters	Baseline,week 1,week 4,week 12,week 24
Secondary	Time to maximum plasma concentration(Tmax)	serum PTH will be tested for all pharmacokinetics parameters	Baseline,week 1,week 4,week 12,week 24
Secondary	Elimination half-life(t1/2)	serum PTH will be tested for all pharmacokinetics parameters	Baseline,week 1,week 4,week 12,week 24